A Two-step Phase 1 Study Investigating the Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients Not Treated Previously With Systemic Therapy.

Trial Profile

A Two-step Phase 1 Study Investigating the Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients Not Treated Previously With Systemic Therapy.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Feb 2013

At a glance

  • Drugs Bevacizumab; Carboplatin; Everolimus; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 27 Apr 2012 Trial phase changed from II to I as reported by ClinicalTrials.gov.
    • 24 Apr 2012 Actual number of patients changed from 52 to 69 as reported by ClinicalTrials.gov.
    • 24 Apr 2012 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top